PD-L1 Antikörper (N-Term)
Kurzübersicht für PD-L1 Antikörper (N-Term) (ABIN4886521)
Target
Alle PD-L1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 41-69, N-Term
-
Verwendungszweck
- Anti-PD-L1/B7-H1/CD274 Antibody Picoband®
-
Sequenz
- KFPVEKQLDL AALIVYWEME DKNIIQFVH
-
Kreuzreaktivität (Details)
- No cross-reactivity with other proteins.
-
Produktmerkmale
- Anti-PD-L1/B7-H1/ Antibody Picoband® (ABIN4886521). Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
-
Aufreinigung
- Immunogen affinity purified.
-
Immunogen
- A synthetic peptide corresponding to a sequence at the N-terminus of human PD-L1/B7-H1, different from the related mouse sequence by ten amino acids.
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
Western blot, 0.1-0.5 μg/mL, Human
1. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., Ahmed, R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687, 2006. 2. Dong, H., Zhu, G., Tamada, K., Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nature Med. 5: 1365-1369, 1999. 3. Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., David, O., Burow, M., and 10 others. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9: 562-567, 2003. -
Kommentare
-
Antibody can be supported by chemiluminescence kit ABIN921124 in WB.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
-
Konzentration
- 500 μg/mL
-
Buffer
- Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
-
Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
-
-
- PD-L1 (CD274 (PD-L1))
-
Andere Bezeichnung
- CD274
-
Hintergrund
-
Synonyms: Programmed cell death 1 ligand 1,PD-L1,PDCD1 ligand 1,Programmed death ligand 1,B7 homolog 1,B7-H1,CD274,CD274,B7H1, PDCD1L1, PDCD1LG1, PDL1,
Tissue Specificity: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. .
Background: Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a protein that in humans is encoded by the CD274 gene. It is mapped to 9p24.1. PD-L1 is a 40 kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. It has been concluded that upregulation of PD-L1 on tumor MDCs downregulates T-cell immunity and that PD-L1 blockade may represent an approach for cancer immunotherapy. Additionally, PD-L1 can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. What's more, it has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer.
-
Molekulargewicht
- 62 kDa
-
Gen-ID
- 29126
-
Pathways
- Cancer Immune Checkpoints
Target
-